Lynparza approved by US FDA for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer
AstraZeneca and MSD’s Lynparza reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy First PARP inhibitor approved in 1st-line maintenance for BRCAm advanced ovarian cancerAstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial